Gefitinib (Iressa)

Epidemiology

  • Indications
    • Non-small cell lung cancer who do not respond to platinum-based chemo agents

Pharmacology

  • Tyrosine Kinase Inhibitor: epidermal growth factor receptor (EGFR) antagonist

Adverse Effects

  • Acute Interstitial Pneumonia/Acute Lung Injury-ARDS (see ILD-Etiology, [[ILD-Etiology]] and Acute Lung Injury-ARDS, [[Acute Lung Injury-ARDS]])
    • Epidemiology: occurs in 1% of cases
      • Nested case control study in Asian population: incidence of 4.5 per 1000 persons over 12-week period
    • Diagnosis
      • Chest CT: ground-glass infiltrates
      • OLB: diffuse alveolar damage
    • Clinical
      • Acute Lung Injury-ARDS: may occur
    • Treatment: corticosteroids might be helpful
    • Prognosis: 30% mortality

References

  • xxx